Source:http://linkedlifedata.com/resource/pubmed/id/10541972
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1999-11-18
|
pubmed:abstractText |
E-cadherin plays an important role in the cell-cell contact of normal epithelium. Loss of E-cadherin expression may be related to tumour invasiveness and metastatic potential. In a group of patients treated for oesophageal carcinoma by radiotherapy only, we found that immunohistochemically detected p53 expression correlated with reduced survival, mainly because of the occurrence of distant metastases. We questioned whether, in this group of patients, E-cadherin expression was concomitantly altered and served as a predictive factor for the development of distant metastases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0171-5216
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
125
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
641-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10541972-Adenocarcinoma,
pubmed-meshheading:10541972-Aged,
pubmed-meshheading:10541972-Cadherins,
pubmed-meshheading:10541972-Carcinoma, Squamous Cell,
pubmed-meshheading:10541972-Disease-Free Survival,
pubmed-meshheading:10541972-Esophageal Neoplasms,
pubmed-meshheading:10541972-Female,
pubmed-meshheading:10541972-Follow-Up Studies,
pubmed-meshheading:10541972-Humans,
pubmed-meshheading:10541972-Immunohistochemistry,
pubmed-meshheading:10541972-Male,
pubmed-meshheading:10541972-Predictive Value of Tests,
pubmed-meshheading:10541972-Survival Rate,
pubmed-meshheading:10541972-Treatment Outcome,
pubmed-meshheading:10541972-Tumor Suppressor Protein p53
|
pubmed:year |
1999
|
pubmed:articleTitle |
E-cadherin expression in oesophageal carcinoma treated with high-dose radiotherapy; correlation with pretreatment parameters and treatment outcome.
|
pubmed:affiliation |
Department of Radiation Oncology, Reinier de Graaf Group, P.O. Box 5011, 2600 GA, Delft, The Netherlands. POMP@RdGG.nl
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|